Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Accelerated approval Phase IV commitments

Executive Summary

FDA's Oncologic Drugs Advisory Committee will meet Nov. 8 to review unfulfilled Phase IV commitments of accelerated approval oncologic drug products. The committee will "identify difficulties associated with completion" of the commitments and provide "advice to sponsors to assist in the planning and execution of postmarketing commitments of newly approved drugs," FDA says. The status of Phase IV commitments for Johnson & Johnson/Alza's Doxil, MedImmune's Ethyol, Ligand/Seragen's Ontak, SkyePharma's DepoCyt, Pfizer's Celebrex, Wyeth's Mylotarg, and Genzyme/Ilex' Campath will be reviewed. Office of Oncology Drugs Director Richard Pazdur said there would be a meeting on the topic during the Sept. 14 review of GlaxoSmithKline's Arranon (1"The Pink Sheet" Sept. 26, 2005, p. 27). The meeting will be held at the Holiday Inn in Gaithersburg, Md. beginning at at 8 a.m.[Editor's Note: To 2watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com]...

You may also be interested in...



Oncology Advisory Cmte. To Review Unfulfilled Accelerated Approval Trials

FDA's Oncologic Drugs Advisory Committee will review products with unfulfilled accelerated approval postmarketing commitments during an upcoming meeting

California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits

The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.

Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer

Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025.  It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046396

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel